Top Markets
#1 Islamic Coin Islamic Coin +154.35%
#2 PulseChain PulseChain +49.22%
#3 BOOK OF MEME BOOK OF MEME +24.70%
#4 edgeX edgeX +16.67%
#5 RedStone RedStone +16.49%
#6 Starpower Starpower +15.93%
#7 Bio Protocol Bio Protocol +12.37%
#8 Lighter Lighter +12.26%
#9 Monad Monad +11.98%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +10.93%
Coin of the day
Islamic Coin Islamic Coin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Immunotech Biopharm Ltd Immunotech Biopharm Ltd

Immunotech Biopharm Ltd

6978
Classifica tra le azioni #27803
Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in... Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in cellular immunotherapy. Its primary activities involve the investigation, development, and market introduction of T cell-based immunotherapy solutions for various cancers within the People's Republic of China. The company's flagship product, EAL, is a multi-target cellular immunotherapy currently undergoing Phase II clinical trials for the purpose of preventing liver cancer recurrence after surgery. Furthermore, Immunotech Biopharm is conducting both preclinical and clinical research on EAL for its potential use in treating lung cancer, glioma, gastric cancer, and colorectal cancer. Other pipeline assets include the 6B11-OCIK injection, which is in Phase I trials for ovarian cancer; the CAR-T-19 injection product, targeting B-cell acute lymphoblastic leukaemia; and a range of TCR-T cell products designed for solid tumor treatment. Established in 2006, the company's main office is located in Beijing, China.
Prezzo delle azioni
$0.0492516
Capitalizzazione di mercato
$30.41M
Variazione (1 giorno)
1.32%
Variazione (1 anno)
-91.28%
Paese
CN
Scambia Immunotech Biopharm Ltd (6978)

Categoria

Healthcare
Ricavi di Immunotech Biopharm Ltd (6978)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Immunotech Biopharm Ltd, i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Immunotech Biopharm Ltd da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH